ICRC-Weyer

What ICRC-Weyer does

ICRC-Weyer GmbH is a Berlin-based, privately held contract research organization founded in 1993 by Prof. Dr. Geerd Weyer as a specialist consultancy in biostatistics, medical writing, and psychometrics. The firm has grown into an integrated all-phase CRO delivering Biostatistics and Clinical Data Management (SAS-based, CDISC Gold Member compliant with CDASH/SDTM/ADaM), Pharmacovigilance Data Management anchored on the VigilanceOne eDrug Safety Database developed with PEI and BfArM, Safety Writing and Pharmacovigilance (DSURs, PSURs/PBRERs, RMPs, signal management), Medical Writing by EMWA-affiliated writers, Medical Review across therapeutic areas, and Scientific Consulting including rater training and trial design. The company maintains an ISO 9001-certified quality management system (TÜV SÜD) and operates from its Berlin headquarters with a secondary Friedrichshagen location, supporting Phase I-IV studies, post-marketing surveillance, investigator-initiated trials, and DiGA/medical device investigations.

The firm monetizes through project-based professional services contracts, offering either a full-service CRO bundle or modular functional services (FSP) to clients that need targeted biostatistics, data management, or medical writing support. Pricing is quote-based via an RFP process; no public price points are disclosed, and contracts are typically multi-year. Its go-to-market is enterprise field sales directed at global pharmaceutical companies, biotech startups, medical device manufacturers, academic investigators, and partner CROs, with delivery in the DACH region and across Europe, supplemented by a partner CRO channel for global reach. The company is family-owned, with management having transitioned in 2019 from founder Prof. Dr. Geerd Weyer to Johann Daniel Weyer (currently Managing Director), who now heads the leadership team.

In January 2026 ICRC-Weyer was acquired by Evestia Clinical, a global independent specialist CRO; the ICRC-Weyer brand, services, and teams are preserved post-transaction, with Johann Daniel Weyer joining the Evestia leadership team. From its ~51-100 employee base, the firm is positioned as a specialist boutique within the European mid-market CRO segment rather than a scaled full-service platform.

Name

ICRC-Weyer

Legal name

ICRC-Weyer GmbH

Website

https://icrc-weyer.com

Company type

Private

Founded year

1993

Operating status

Acquired

Headcount range

51–100 employees

Short description

ICRC-Weyer GmbH is a Berlin-based, all-phase contract research organization founded in 1993 that delivers biostatistics, clinical data management, pharmacovigilance, medical writing, and scientific consulting to pharmaceutical, biotech, medical device, academic, and partner CRO clients across Europe.

Ownership category

akta.pro rank

Product category

Contract Research Services

NAICS

Scientific Research and Development Services (5417)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Medical Writing & Regulatory Submission Support CROs (HLAGAAAG), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF), Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH)

Keywords

• Contract research organization
• Clinical data management
• Biostatistics services
• Pharmacovigilance services
• Medical writing

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Full-service CRO providing comprehensive clinical research services including biostatistics, clinical data management, medical writing, pharmacovigilance, and safety writing. Revenue generated through project-based professional services contracts with pharmaceutical and biotech companies.
2. Functional Services (FSP): Individual functional services contracted separately based on customer needs - allowing flexibility for clients who only need specific services rather than full-service packages.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

ICRC-Weyer is a specialized Contract Research Organization (CRO) providing modular and full-service clinical research solutions across all trial phases. Core offerings include biostatistics and clinical data management, pharmacovigilance and safety writing, medical writing, medical review, and scientific consulting for pharmaceutical, biotech, medical device, academic, and partner CRO clients.

Product overview

ICRC-Weyer is an integrated all-phase Contract Research Organization (CRO) and scientific consultancy based in Berlin, Germany, founded in 1993. Its portfolio consists of multiple specialized service lines offered both as a full-service package and as individual functional services. The core offering spans Biostatistics & Clinical Data Management (CDISC Gold Member, SAS-based systems), Pharmacovigilance Data Management (using VigilanceOne), Safety Writing & Pharmacovigilance (pre- and post-marketing), Medical Writing (EMWA-affiliated writers), Medical Review (per-patient to condensed review approaches), Scientific Consulting (rater training, expert opinions, trial design), all delivered as an integrated all-phase CRO covering Phase I-IV clinical trials, non-interventional studies, investigator-initiated trials, and post-marketing surveillance.

Differentiator

Problem solved

Functional benefit

Products and services

• Full Service CRO Provides the complete range of CRO services as an integrated all-phase CRO, from study setup and conduct to data handling, analysis and reporting across all study phases and post-marketing surveillance trials. Available in the DACH region, across Europe, and globally.
• Biostatistics & Clinical Data Management Provides biostatistics support including study design, sample size estimation, statistical analysis for Phase I-IV clinical trials, and pharmacokinetic/pharmacodynamic analysis, combined with clinical data management covering EDC setup, CRF design, database design, and query management, operating as a CDISC Gold Member with SAS-based systems.
• Pharmacovigilance Data Management Offers user support for safety databases, data migration and conversion, database analyses and quality control, and systematic data reviews, built on expertise combining medical data management and pharmacovigilance with long-term software development partners.
• Safety Writing & Pharmacovigilance Provides pre- and post-marketing pharmacovigilance services including SAE/AE reporting, expedited reporting, DSURs, PSURs/PBRERs, Risk Management Plans, signal management, and benefit-risk assessments. Utilizes the VigilanceOne eDrug Safety Database compliant with ICH-E2B and regulatory authority requirements.
• Medical Writing Delivers regulatory medical writing for drugs, medical devices, and nutritional products, covering clinical study protocols, clinical investigation plans, clinical study reports, patient informed consent forms, investigator brochures, and common technical documents, with all writers being members of the European Medical Writers Association (EMWA).
• Medical Review Provides medical review services ranging from condensed listing reviews to 100% expert review of all safety and efficacy data at the per-patient level, drawing on a network of medical experts in neurology, ophthalmology, anesthesiology, internal medicine, and oncology.
• Scientific Consulting Offers scientific consulting including rater trainings, expert opinions and reports, trial design, methodological consulting, literature review, and specialized expertise in advanced therapies, clinical pharmacology, psychometrics, CNS, gastroenterology, dermatology, rheumatology, and Phase I trials.

Quantifiable outcome

• 968 projects successfully completed since 1993
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Evestia ClinicalcoreOthers · 27 January 2026ICRC-Weyer GmbH was acquired by Evestia Clinical, a leading independent global specialist CRO. ICRC-Weyer continues to operate under its brand with no changes to services or teams. Managing Director Johann Daniel Weyer joins Evestia Clinical leadership team. Acquisition enhances Evestia Clinical's specialist capabilities in biostatistics, data management, and medical writing while strengthening presence in Germany and Europe.
• VigilanceOne (Drug Safety Database)coreTechnology or IntegrationVigilanceOne is an eDrug Safety Database developed in cooperation with German regulatory authorities Paul-Ehrlich-Institut (PEI) and Federal Institute for Drug and Medical Devices (BfArM). ICRC-Weyer utilizes this system for pharmacovigilance services, compliant with ICH-E2B and regulatory authority requirements. Supports E2B data exchange via Eudravigilance gateway.
• CDISCcoreTechnology or IntegrationCDISC Gold Member. ICRC-Weyer intensively supports and fully complies with CDASH, SDTM and ADaM standards for clinical data management and biostatistics. CDISC membership demonstrates commitment to industry data standards.
• European Medical Writers Association (EMWA)minorOthersICRC-Weyer employees are active members of EMWA. Company sponsors EMWA conferences and employees participate in workshops and education programs. Supports professional development of medical writing staff.
• PAREXEL AcademyminorOthersManaging Director Johann Daniel Weyer teaches at PAREXEL Academy for more than 10 years, in addition to holding industry trainings for other institutions or directly via ICRC-Weyer. Also teaches at Colloquium Pharmaceuticum.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• FGK Clinical Research: FGK Clinical Research is a Munich-based mid-size CRO offering clinical trial management, biostatistics, medical writing, and pharmacovigilance services to pharma, biotech, and medical device sponsors. Highly comparable as a German-rooted, mid-sized specialty CRO competing for the same sponsor RFPs in DACH and across Europe.
• Smerud Medical Research: Smerud Medical Research is a Norway-headquartered European CRO providing biostatistics, clinical study management, medical writing, and pharmacovigilance across all trial phases. Directly comparable in scale, service mix, and Northern European/DACH-serving footprint.
• Ergomed: Ergomed is a UK-based mid-size CRO specializing in clinical research, biostatistics, and pharmacovigilance services, particularly for oncology and rare disease. Comparable mid-sized specialty CRO profile competing for similar European and global FSP and full-service engagements.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-size global CRO offering full-service clinical development, biostatistics, and pharmacovigilance services to biotech and pharma. Comparable mid-tier CRO competing for similar Phase I-IV and post-marketing engagements.
• Clinipace Worldwide: Clinipace Worldwide is a mid-size global CRO providing biostatistics, clinical data management, medical writing, and full-service clinical trial management. Direct competitor in the mid-tier CRO segment serving similar biotech and specialty pharma clients.
• Rho: Rho is a US-based CRO and contract research organization focused on biostatistics, clinical data management, and regulatory submissions for pharma and biotech sponsors. Highly comparable in the biostatistics/CDM niche and competes for similar FSP contracts.
• Premier Research: Premier Research is a mid-size CRO providing clinical research, biostatistics, medical writing, and pharmacovigilance services across all phases with particular strength in specialty therapeutic areas. Direct mid-tier competitor for similar sponsor mandates.

Broad incumbents

• Parexel International: Parexel is one of the world's largest CROs offering full-service clinical development, biostatistics, regulatory, and pharmacovigilance across all major geographies. Serves as the broader incumbent against which ICRC-Weyer competes for global sponsor programs and where the Managing Director has taught at its Academy.
• ICON plc: ICON plc is a global full-service CRO offering clinical research, biostatistics, data management, and pharmacovigilance services at scale. Serves as a broad incumbent competitor for large multinational sponsor engagements.
• IQVIA: IQVIA is the largest global CRO and life sciences services provider, offering comprehensive clinical development, biostatistics, real-world evidence, and pharmacovigilance. Represents the largest incumbent competitor against which ICRC-Weyer positions its boutique specialty services.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/icrc-weyer-gmbh

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ICRC-Weyer